Prot# SARC019: A Randomized, Phase 3 Study of Dose Escalation Versus No Dose Escalation of Imatinib in Metastatic GIST Patients with Imatinib Trough Levels Less Than 1100 nanograms/mL

  • Agulnik, Mark (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date8/20/10 → 8/20/13

Funding

  • SARC (SARC019)
  • Novartis Pharmaceuticals Corporation (SARC019)